BR112022018157A2 - Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer - Google Patents
Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncerInfo
- Publication number
- BR112022018157A2 BR112022018157A2 BR112022018157A BR112022018157A BR112022018157A2 BR 112022018157 A2 BR112022018157 A2 BR 112022018157A2 BR 112022018157 A BR112022018157 A BR 112022018157A BR 112022018157 A BR112022018157 A BR 112022018157A BR 112022018157 A2 BR112022018157 A2 BR 112022018157A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- treatment
- prevention
- drug
- efficacy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020043021 | 2020-03-12 | ||
| PCT/JP2021/009798 WO2021182573A1 (ja) | 2020-03-12 | 2021-03-11 | 癌の治療及び/又は予防のための医薬品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018157A2 true BR112022018157A2 (pt) | 2022-10-25 |
Family
ID=77671643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018157A BR112022018157A2 (pt) | 2020-03-12 | 2021-03-11 | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método para o tratamento e/ou prevenção do câncer |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230129035A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4119156A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7797875B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220152318A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022018157A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175137A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021182573A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2322221T3 (da) * | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| CA3175127A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2022319362A1 (en) * | 2021-07-27 | 2024-02-29 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240042415A (ko) * | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| EP4378478A4 (en) * | 2021-07-27 | 2025-11-12 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| JPWO2024043252A1 (cg-RX-API-DMAC7.html) * | 2022-08-24 | 2024-02-29 | ||
| AU2023329564A1 (en) * | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CN119768181A (zh) * | 2022-08-24 | 2025-04-04 | 东丽株式会社 | 用于癌的治疗和/或预防的药品 |
| AU2024236246A1 (en) * | 2023-03-14 | 2025-10-30 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE340590T1 (de) | 1994-07-13 | 2006-10-15 | Chugai Pharmaceutical Co Ltd | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| SK14812000A3 (sk) | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| DE10359795A1 (de) | 2003-12-19 | 2005-07-21 | Bayer Technology Services Gmbh | Strangverdampfervorrichtung |
| DK2322221T3 (da) | 2008-08-05 | 2014-09-01 | Toray Industries | Farmaceutisk sammensætning til behandling og forebyggelse af cancer |
| BRPI1015234A2 (en) | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| KR101871704B1 (ko) | 2010-02-04 | 2018-06-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| BR112012018951C8 (pt) | 2010-02-04 | 2020-06-23 | Toray Industries | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
| HUE040012T2 (hu) | 2010-02-04 | 2019-02-28 | Toray Industries | Gyógyászati ágens rák kezelésére és/vagy megelõzésére |
| AU2011211699B2 (en) | 2010-02-04 | 2015-01-22 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
| JP5845899B2 (ja) | 2010-02-04 | 2016-01-20 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| ES2672695T3 (es) | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| BR112014002619A2 (pt) | 2011-08-04 | 2018-10-09 | Toray Industries, Inc | composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica |
| AU2013223143B2 (en) | 2012-02-21 | 2017-12-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| IN2014KN01714A (cg-RX-API-DMAC7.html) | 2012-02-21 | 2015-10-23 | Toray Industries | |
| PT2832365T (pt) | 2012-03-30 | 2018-01-24 | Toray Industries | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático |
| US9428581B2 (en) | 2012-03-30 | 2016-08-30 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| WO2018234879A1 (en) * | 2017-06-22 | 2018-12-27 | Novartis Ag | USE OF IL-1β BINDING ANTIBODIES IN THE TREATMENT OF CANCER |
| WO2019189780A1 (ja) | 2018-03-30 | 2019-10-03 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
| JP7103097B2 (ja) | 2018-09-13 | 2022-07-20 | トヨタ自動車株式会社 | 燃料電池車両 |
-
2021
- 2021-03-11 JP JP2021532006A patent/JP7797875B2/ja active Active
- 2021-03-11 BR BR112022018157A patent/BR112022018157A2/pt unknown
- 2021-03-11 WO PCT/JP2021/009798 patent/WO2021182573A1/ja not_active Ceased
- 2021-03-11 CA CA3175137A patent/CA3175137A1/en active Pending
- 2021-03-11 EP EP21767020.7A patent/EP4119156A4/en active Pending
- 2021-03-11 KR KR1020227035364A patent/KR20220152318A/ko active Pending
- 2021-03-11 US US17/910,538 patent/US20230129035A1/en active Pending
-
2025
- 2025-03-27 JP JP2025053695A patent/JP2025092589A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021182573A1 (ja) | 2021-09-16 |
| JPWO2021182573A1 (cg-RX-API-DMAC7.html) | 2021-09-16 |
| JP7797875B2 (ja) | 2026-01-14 |
| US20230129035A1 (en) | 2023-04-27 |
| JP2025092589A (ja) | 2025-06-19 |
| EP4119156A1 (en) | 2023-01-18 |
| KR20220152318A (ko) | 2022-11-15 |
| CA3175137A1 (en) | 2021-09-16 |
| EP4119156A4 (en) | 2024-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| BR112023000687A2 (pt) | Métodos e combinações de inibidores de kat6 para o tratamento de câncer | |
| Zheng et al. | Nonsteroidal anti-inflammatory drugs versus corticosteroid for treatment of shoulder pain: a systematic review and meta-analysis | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
| BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
| BR112022018166A2 (pt) | Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer | |
| MX2023000763A (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas. | |
| BR112022018171A2 (pt) | Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer | |
| Gönül et al. | Effect of submucosal application of tramadol on postoperative pain after third molar surgery | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| BR112022008191A2 (pt) | Terapia com antagonista de lag-3 para melanoma | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112023002085A2 (pt) | Métodos para tratar hipercolesterolemia refratária envolvendo inibidor de angptl3 | |
| BR112023002883A2 (pt) | Conjunto de composições para tratamento bucal anticárie | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| BR112022020683A2 (pt) | Anticorpos e composições anti-flt3 | |
| MX2023014500A (es) | Medicamento para el tratamiento y/o prevencion de cancer. | |
| BR112022003323A2 (pt) | Método terapêutico ou profilático para diabetes usando medicina de combinação | |
| BR112022022378A2 (pt) | Métodos para tratamento da doença de crohn com anticorpo específico anti-il23 | |
| Carroll et al. | Management of chronic pain following nerve injuries/CRPS type II | |
| BR112022009510A2 (pt) | Análogo de insulina, composição farmacêutica, e, método de tratamento, prevenção ou alívio de uma doença ou distúrbio ou condição | |
| BR112022017466A2 (pt) | Terapia combinada com um inibidor de idh mutante e um inibidor de bcl-2 |